Bisphosphonates for osteoporosis

New England Journal of Medicine

Volumn 363, Issue 21, 2010, Pages 2027-2035

  Favus, Murray J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CLODRONIC ACID; ESTROGEN; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BLEEDING; BONE CANCER; BONE DISEASE; BONE PAIN; BREAST CANCER; CLINICAL TRIAL; COMPRESSION FRACTURE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; FEMUR FRACTURE; FEVER; HEARTBURN; HIP FRACTURE; HOARSENESS; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; MYALGIA; MYELOMA; NEPHROTOXICITY; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; THORAX PAIN; TREATMENT FAILURE; ULCER; VERTEBRA FRACTURE; VOCAL CORD DISORDER; WEAKNESS;

EID: 78549264482     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMct1004903     Document Type: Article

References (54)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95.
2. Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002;87:4431-7. (Pubitemid 35247019)
3. Jamal SA, Leiter RE, Bayoumi AM, Bauer DC, Cummings SR. Clinical utility of laboratory testing in women with osteoporosis. Osteoporos Int 2005;16:534-40.
4. Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD: Department of Health and Human Services, 2004.
5. Advisory Group on Osteoporosis. Report. London: Department of Health, 1994.
6. Management of osteoporosis in post-menopausal women: 2010 position statement of the North American Menopause Society. Menopause 2010;17:25-54.
7. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ III. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001-5.
8. Haentjens P, Magaziner JS, Colón-Emeric CS, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010;152:380-90.
9. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115:3318-25.
10. Khosla S. Pathogenesis of osteoporosis. In: Robertson RP, ed. Translational endocrinology & metabolism: osteoporosis update. Chevy Chase, MD: The Endocrine Society, 2010:55-86. (http://www.endojournals.org/ translational/issues/osteoporosis.pdf.)
11. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006;354:2250-61.
12. Hofbauer LC, Schoppet M. Bone biology underlying therapeutic approaches. In: Robertson RP, ed. Translational endocrinology & metabolism: osteoporosis update. Chevy Chase, MD: The Endocrine Society, 2010:117-48. (http://www.endojournals.org/translational/issues/osteoporosis.pdf.)
13. Rodan G, Reszka A, Golub E, Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 2004;20:1291-300. (Pubitemid 39120794)
14. McClung MR. Bisphosphonates. Endocrinol Metab Clin North Am 2003;32:253-71.
15. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59.
16. Sato M, Grasser W, Endo N, et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-105.
17. Masarachia P, Weinreb M, Balena R, Rodan GA. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996;19:281-90.
18. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan GA. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000;373:231-41.
19. Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 1999;96:133-8.
20. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell RG, Rogers MJ. Nitrogen-containing bisphosphonates inhibit mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-9.
21. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
22. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999;282:1344-52.
23. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40.
24. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22. (Pubitemid 46698462)
25. Chestnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9.
26. McCloskey E, Selby P, Davies M, et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a doubleblind, placebo-controlled 3-year study. J Bone Miner Res 2004;19:728-36.
27. Wells GA, Cranney A, Peterson J, et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;1:CD003376.
28. Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:517-23.
29. Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ III. The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int 2010;21:41-52.
30. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
31. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729-38. (Pubitemid 37430623)
32. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:524-8.
33. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:540-51.
34. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38.
35. Adami S, Bhalla AK, Dorizzi R, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987;41:326-31.
36. Ribeiro A, DeVault KR, Wolfe JT III, Stark ME. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc 1998;47:525-8.
37. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010;95:1555-65.
38. Lewiecki EM, Miller PD. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf 2007;6:663-72.
39. Boonen S, Sellmeyer DE, Lippuner K, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008;74:641-8.
40. Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K. Bisphosphonate- induced hypocalcemia: report of 3 cases and review of the literature. Endocr Pract 2006;12:48-53.
41. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
42. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91. (Pubitemid 351229318)
43. Bilezikian JP. osteonecrosis of the jaw - do bisphosphonates pose a risk? N Engl J Med 2006;355:2278-81.
44. Woo SB, Hellstein JW, Kalmar JR. Systemic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61. [Erratum, Ann Intern Med 2006;145:235.]
45. Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med 2010;362:1825-7.
46. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009;24:1095-102.
47. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010;362:1761-71.
48. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301.
49. Stepan JJ, Burr DB, Pavo I, et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 2007;41:378-85.
50. Chapurlat RD, Arlot M, Burt-Pichat B, et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 2007; 22:1502-9. [Erratum, J Bone Miner Res 2008;23:1153.]
51. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008.
52. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003;9:544-64. [Erratum, Endocr Pract 2004;10:90.]
53. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:404-15.
54. American College of Obstetricians and Gynecologists Women's Health Care Physicians. Osteoporosis. Obstet Gynecol 2004;104:Suppl:66S-76S.